Nipro Medical Corporation, based in Bridgewater, NJ, is a wholly-owned subsidiary of Nipro Corporation, based in Japan. The company's North American Division today announced a significant U.S. expansion with a nearly $400 million investment to build its first North American manufacturing facility in Greenville, North Carolina.
The new plant will generate 232 jobs and include a $398 million investment over the next five years. Nipro Medical manufactures a range of renal, vascular and surgical products.
The new plant should help Nipro significantly reduce global transportation needs, cutting down on carbon emissions, which is key to the company's drive to minimize environmental impact.
Tsuyoshi Yamazaki, senior managing director of global business at Nipro, says the new facility in Greenville is a significant milestone in the company's sustainability journey. "We are thrilled to start manufacturing our cutting-edge medical devices in the U.S., which will support local healthcare professionals and patients with a stable supply chain and reduced transportation costs," said Yamazaki. "Our close proximity to customers will allow us to better respond to their needs and provide them with timely and effective solutions."
The new facility in Pitt County marks Nipro's first venture into producing advanced medical devices directly in the U.S. market. The advanced manufacturing site will host a range of positions, from engineering and production to administrative and management roles. Nipro values ownership, flexibility, and team spirit among its employees.
The North Carolina facility will make state-of-the-art medical devices that support patients with diabetes, chronic kidney disease, and other renal health issues.
